Restore Vision

Restore Vision is a Japanese biotechnology startup with a mission to address the challenges posed by intractable eye diseases. The company, founded in 2016, aims to develop treatments using advanced technology to combat conditions for which no prevention or treatment methods currently exist. Their commitment is underscored by the staggering statistics, with over 300,000 visually impaired patients in Japan and the associated social cost exceeding 8 trillion yen. The impact of vision loss on the patients' quality of life, depriving them of 80% of external information, is a driving force for the team. Their recent ¥600.00M Series A investment in December 2023 from notable investors such as JIC Venture Growth Investments, Remiges Ventures, Kyoto University Innovation Capital Co., Ltd, and Osaka University Venture Capital underscores the recognition and support the startup has garnered. With a headquarter in Japan, Restore Vision is poised to make significant strides in revolutionizing the treatment landscape for eye diseases, setting the stage for a brighter future for countless individuals.